Table 1.
The baseline characteristics of the study population, by BMI category.
| Characteristic | Underweight (N = 20) | Normal weight (N = 95) | Overweight (N = 90) | Obese (N = 124) | P value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Median (IQR) or n (%) | Missing data | Median (IQR) or n (%) | Missing data | Median (IQR) or n (%) | Missing data | Median (IQR) or n (%) | Missing data | ||
| Age | 84.5 (71.3–89) | 81 (69–87) | 71 (62.3–83) | 66 (53–76.3) | <0.001 | ||||
| Females | 12 (60%) | 43 (45.3%) | 30 (33.3%) | 58 (46.8%) | 0.083 | ||||
| Smoking history | 8 | 23 | 23 | 26 | 0.12 | ||||
| Never smokers | 7 (35%) | 42 (44.2%) | 36 (40%) | 69 (55.6%) | |||||
| Past smokers | 4 (20%) | 25 (26.3%) | 29 (32.2%) | 22 (17.8%) | |||||
| Current smokers | 1 (5%) | 5 (5.3%) | 2 (2.2%) | 7 (5.6%) | |||||
| Comorbidities | |||||||||
| Diabetes | 2 (10%) | 20 (21.1%) | 34 (37.8%) | 37 (29.9%) | 0.019 | ||||
| Arterial hypertension | 9 (45%) | 55 (57.9%) | 63 (70%) | 75 (60.4%) | 0.13 | ||||
| Hyperlipidemia | 6 (30%) | 34 (35.8%) | 33 (36.7%) | 36 (29%) | 0.61 | ||||
| Total CVD | 11 (55%) | 32 (33.7%) | 1 | 38 (42.2%) | 34 (27.4%) | 0.033 | |||
| Cardiac disease | 10 (50%) | 23 (24.2%) | 1 | 31 (34.4%) | 27 (21.8%) | 0.022 | |||
| SAS | 0 | 2 (2.1%) | 5 (5.6%) | 11 (8.9%) | 0.13 | ||||
| COPD | 5 (25%) | 16 (16.8%) | 5 (5.6%) | 8 (6.5%) | 0.005 | ||||
| CKD | 2 (10%) | 14 (14.7%) | 15 (16.7%) | 19 (15.3%) | 0.94 | ||||
| Cancer | 4 (20%) | 22 (23.2%) | 1 | 16 (17.8%) | 11 (8.9%) | 0.021 | |||
| Main symptoms | |||||||||
| Cough | 7 (35%) | 1 | 41 (43.2%) | 1 | 44 (48.9%) | 1 | 66 (53.2%) | 0.35 | |
| Fever | 9 (45%) | 1 | 58 (61.1%) | 1 | 59 (65.6%) | 1 | 88 (71%) | 0.15 | |
| Main drug categories | |||||||||
| Metformin | 1 (5%) | 14 (14.7%) | 18 (20%) | 22 (17.7%) | 0.41 | ||||
| ACEIs | 5 (25%) | 23 (24.2%) | 18 (20%) | 23 (18.5%) | 0.72 | ||||
| ARBs | 2 (10%) | 11 (11.6%) | 15 (16.7%) | 20 (16.1%) | 0.71 | ||||
| Main laboratory findings on admission | |||||||||
| Glycemia (mmol/l) | 5.8 (5.2–6.7) | 1 | 6.5 (5.5–7.9) | 12 | 6.8 (5.7–8.7) | 6 | 6.8 (5.9–8.1) | 10 | 0.05 |
| GFR (MDRD ml/min/1.73 m²) | 86 (59.8–123) | 88.5 (57–110.3) | 1 | 79 (61–91) | 1 | 79 (48.8–106.3) | 0.20 | ||
| WBC count × 109 per L | 7.3 (6.1–9.0) | 6.2 (4.7–9.2) | 1 | 6.5 (5.2–9.1) | 1 | 6.7 (5.0–9.0) | 0.52 | ||
| Lymphocyte count × 109 per L | 1.0 (0.8–1.1) | 0.8 (0.6–1.1) | 1 | 0.8 (0.5–1.3) | 1 | 0.9 (0.7–1.2) | 0.59 | ||
| CRP mg/l | 68.7 (34–126.9) | 71.8 (24.7–137.5) | 1 | 96.7 (52–155.9) | 2 | 106.4 (54–185.8) | 0.008 | ||
| ALAT > 40 U/l | 0 | 3 | 30 (31.6%) | 10 | 28 (31.1%) | 8 | 50 (40.3%) | 7 | 0.007 |
| ASAT > 40 U/l | 4 (20%) | 3 | 49 (51.6%) | 10 | 48 (53.3%) | 8 | 71 (57.3%) | 7 | 0.036 |
| GGT > ULN | 7 (35%) | 4 | 38 (40%) | 12 | 44 (48.9%) | 14 | 55 (44.3%) | 10 | 0.41 |
| Albumin (g/l) | 26.6 (22.2–28.6) | 5 | 26.6 (22.5–30) | 23 | 26 (20.6–30.4) | 23 | 25.8 (22.4–29.6) | 47 | 0.89 |
ACEI angiotensin-converting–enzyme inhibitor, ALAT alanine transaminase, ARB angiotensin receptor blocker, ASAT aspartate transaminase, BMI body mass index, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, CVD cardiovascular disease, GFR (MDRD) glomerular filtration rate, as estimated with the Modification of Diet in Renal Disease equation, GGT gamma-glutamyltranspeptidase, IQR interquartile range, SAS sleep apnea syndrome, ULN upper limit of normal, WBC white blood cell.
Bold values indicates significant P values.